Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.9052W HIGH $11.71
Volume
25.05 K
Value Traded
361.42 K
Short % Float
10.86%
-3.85%Week
-5.36%1 Month
-4%3 Month
+49.25%6 Month
-32.73%5 Year
-80.35%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
75.16 M
EPS (TTM)
0.40
P/E Ratio
14.82
Ent. Value
60.24 M
Total Shares
12.53 M
Float Shares
10.48 M
Insiders
16.76%
Institutions
53.14%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LFVN Catalyst Timeline
Dated clinical, regulatory and corporate events for Lifevantage Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lifevantage Corporation
101Total events
0Upcoming
1Tier-1 (high impact)
2009 to 2026Coverage
Event history 50
◆Quarterly UpdateCorporate
Fiscal 2026 revenue, adjusted EBITDA, and adjusted EPS expected near lower end of prior guidance range
▼Quarterly UpdateCorporate
Received NASDAQ notice of non-compliance with Listing Rule 5250(c)(1)
▼Quarterly UpdateCorporate
Received NASDAQ letter for non-compliance with Listing Rule 5250(c)(1)
▲Quarterly UpdateCorporate
LifeVantage reports Q3 fiscal 2016 revenue of $56.2M, net income $1.0M
●Quarterly UpdateCorporate
LifeVantage reports Q2 fiscal 2016 revenue of $52M, net income $1.6M
▲Other Regulator MilestoneEx-US Regulatory
Plan for expansion into European Union with entry in UK and Netherlands
●Quarterly UpdateCorporate
LifeVantage reports Q1 fiscal 2016 revenue of $45.4M and adjusted EBITDA of $4.5M
▼Reverse Stock SplitCorporate
Board approves reverse stock split proposal to maintain NASDAQ listing
▼Quarterly UpdateCorporate
Company revises FY2013 guidance: revenue $207-212M, EPS $0.06-0.07
▲Equity OfferingCorporate
Company announces intent to pursue $30-40M credit facility for share repurchases
◆Quarterly UpdateCorporate
Board exploring options to reduce outstanding shares; engaging investment bank
▲Quarterly UpdateCorporate
LifeVantage reports Q2 fiscal 2013 results with net revenue of $53.4M
●Runway Guidance UpdateCorporate
Reiterates FY2013 revenue guidance of $250M-$260M; revises profitability guidance
▲Other Regulator MilestoneProtandimEx-US Regulatory
Full business operations underway in Japan
▼RecallProtandimCMC / Inspection
Voluntary recall and replacement of select lots of Protandim due to potential metal fragments
▲IP Litigation RulingIP / Competition
Lawsuit Bramwell v. LifeVantage Corporation dismissed voluntarily by plaintiff
Past FDA Catalysts and PDUFA Decisions
How LFVN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every LFVN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lewis DarwinDirector | Buy | 976 138,244 held | $6.22 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LFVN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LFVN for Q2 2026. | ||||
LFVN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LFVN ranks across every disease it competes in
Competitive Position is a premium feature
See how LFVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLFVN News
LFVN▲ +9.3%on this news
LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2026
LifeVantage Corporation (Nasdaq: LFVN) reported third-quarter fiscal 2026 results, showing a revenue decline of 25.2% compared to the same period last year, primarily attributed to reduced sales of its MindBody GLP-1 System. The company's net income per diluted share dropped to $0.11, down from $0.26, while adjusted EBITDA also fell significantly. Despite these challenges, LifeVantage emphasized its strong balance sheet, share repurchase activities, and an increase in its cash dividend. The company aims to enhance performance through strategic initiatives and product launches moving forward.
Read more →LFVN▲ +5.1%on this news
LifeVantage Appointing Terrence Moorehead as Chief Executive Officer
LifeVantage Corporation has appointed Terrence Moorehead as the new President and Chief Executive Officer, effective August 5, 2026. Moorehead, who has over 25 years of experience in leading transformations within the health and wellness industry, previously served as CEO of Nature's Sunshine Products, where he achieved significant revenue and EBITDA growth. His appointment follows the planned retirement of the former CEO, Steve Fife, and the Board expresses confidence in Moorehead's ability to guide the company through its next phase of growth. The interim leadership team will maintain operations until Moorehead officially joins the company.
Read more →LFVNDocument LifeVantage Appoints Cindy Latham to Board of Directors Salt Lake City, UT
LifeVantage Appoints Cindy Latham to Board of Directors Salt Lake City, UT, February 17, 2022, (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq LFVN) today announced the appointment of Cindy Latham to the Company's Board of Directors. Latham is a senior-level marketing execut
Read more →LFVNDocument LifeVantage Appoints Carl Aure as Chief Financial Officer Salt Lake City, UT
LifeVantage Appoints Carl Aure as Chief Financial Officer Salt Lake City, UT, October 25, 2021, (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq LFVN) today announced the appointment of Carl Aure as Chief Financial Officer. Mr. Aure brings more than 24 years of finance and ac
Read more →LFVNDocument LifeVantage Announces Appointment of Chief Executive Officer Steven R. Fife Named President, CEO Director Salt Lake City, UT
LifeVantage Announces Appointment of Chief Executive Officer Steven R. Fife Named President, CEO Director Salt Lake City, UT, February 2, 2021, (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq LFVN) announced today that its Board of Directors has named Steven Fife as Preside
Read more →LFVNDocument LifeVantage Announces Management Transition Steven Fife Appointed Interim Chief Executive Officer Justin Rose to Lead Combined Sales Marketing Team Reiterates Fiscal 2021 Guidance Salt Lake City, UT
LifeVantage Announces Management Transition Steven Fife Appointed Interim Chief Executive Officer Justin Rose to Lead Combined Sales Marketing Team Reiterates Fiscal 2021 Guidance Salt Lake City, UT, September 8, 2020, (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq LFVN)
Read more →LFVNLifeVantage Reports Record Second Quarter Preliminary Revenue
LifeVantage Reports Record Second Quarter Preliminary Revenue Q2 preliminary revenue of approximately $58 million represents the highest quarterly revenue in the company's history Revenue increased approximately 17% year over year and 4% sequentially Salt Lake City, UT, Januar
Read more →LFVNThis Indemnification Agreement, effective as of _____ __, ____, is made between LifeVantage Corporation, a Delaware corporation (the "Company"), and _________ (the "Indemnitee").
LifeVantage Corporation INDEMNIFICATION AGREEMENT This Indemnification Agreement, effective as of _____ __, ____, is made between LifeVantage Corporation, a Delaware corporation (the "Company"), and _________ (the "Indemnitee"). A.The Company desires to attract and retain the
Read more →LFVNThis document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
LifeVantage Further Enhances Management Team with Appointment of Steven R. Fife as Chief Financial Officer SALT LAKE CITY, March 13, 2017 - LifeVantage Corporation (Nasdaq:LFVN), announced today the appointment of Steven R. Fife as Chief Financial Officer, effective immediately
Read more →LFVNLifeVantage Announces Management Change
LifeVantage Announces Management Change Gary Koos to Assume Role as Interim Chief Financial Officer SALT LAKE CITY, January 18, 2017 - LifeVantage Corporation (Nasdaq:LFVN), announced today the appointment of Gary Koos as Interim Chief Financial Officer, effective January 19, 2
Read more →LFVNLifeVantage Announces Financial Results for Fiscal Year 2016 and the First Quarter of Fiscal 2017
LifeVantage Announces Financial Results for Fiscal Year 2016 and the First Quarter of Fiscal 2017 Company files Forms 10-K and 10-Q for periods ended June 30, 2016 and September 30, 2016, respectively Expects to regain compliance with Nasdaq listing rules First Quarter of Fis
Read more →LFVNLifeVantage Corp.
LifeVantage Corp. Receives NASDAQ Letter Related to Delay in Filing Form 10-Q SALT LAKE CITY, UT, November 18, 2016 - LifeVantage Corporation (NASDAQ: LFVN) announced today that in connection with its November 10, 2016 notification of late filing of the Company's Form 10-Q for t
Read more →LFVNLifeVantage Receives Limited Waiver and Extension Under Credit Facility
LifeVantage Receives Limited Waiver and Extension Under Credit Facility SALT LAKE CITY, UT, October 26, 2016 - LifeVantage Corporation (NASDAQ: LFVN) announced today that it has received a limited waiver and extension from Zions Bank, the lender under the company's credit facili
Read more →LFVNLifeVantage Appoints WSRP, LLC as its New Independent Auditor
LifeVantage Appoints WSRP, LLC as its New Independent Auditor The Company dismissed BDO USA, LLP as its independent auditor due to BDO USA's determination that it was not independent of the Company with respect to fiscal 2016 Salt Lake City, UT, July 13, 2016, LifeVantage Corpo
Read more →LFVNLifeVantage Announces Third Quarter Fiscal Year 2016 Results
LifeVantage Announces Third Quarter Fiscal Year 2016 Results Reports Record Quarterly Revenue of $56.2 Million Third Quarter Revenue Increased 24.4% year over year Third Quarter Americas Revenue increased 33.8% year over year Company Narrows Fiscal 2016 Guidance Salt Lake Ci
Read more →LFVNLifeVantage Announces Refinancing of Term Loan
LifeVantage Announces Refinancing of Term Loan New three-year term loan with Zions Bank provides reduced interest rate and extended maturity Salt Lake City, UT, April 4, 2016, LifeVantage Corporation (Nasdaq: LFVN), announced today that it has entered into a new $10 million thr
Read more →LFVNLifeVantage Announces Second Quarter Fiscal Year 2016 Results
LifeVantage Announces Second Quarter Fiscal Year 2016 Results Second Quarter Revenue Increased 7.8% to $52 Million Compared to Same Period Last Year Revenue in the Americas and Asia/Pacific increased 15.3% and 12.4% on a Sequential Basis Revenue in Japan increased 7.3% on a Se
Read more →LFVNLifeVantage Announces First Quarter Fiscal Year 2016 Results
LifeVantage Announces First Quarter Fiscal Year 2016 Results First Quarter Revenue was $45.4 Million Adjusted EBITDA Increased 43% sequentially to $4.5 million in First Quarter Company Reiterates Fiscal 2016 Guidance Announced New Products Announced Plan for Expansion into E
Read more →About Lifevantage Corporation
Headquarters3300 TRIUMPH BLVD, LEHI, UT, 84043
BIOPHARMAWATCH ELITE PLUS
Trade the next LFVN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime